Clinical decision support to help consider SGLT2 inhibitors after AKI in type 2 diabetes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pilot adaptive cluster randomized trial investigates whether sending a brief clinical decision support message to providers or clinic pharmacists influences consideration and prescribing of SGLT2 inhibitors in adults with type 2 diabetes and recent AKI. Participating primary care clinics are randomized to receive the CDS intervention or continue standard care. The study focuses on feasibility outcomes, such as identifying eligible patients, delivering CDS messages, and tracking whether SGLT2 inhibitors are considered or prescribed, along with follow-up kidney function data. The investigators do not provide medications; prescribing decisions remain with the patient’s usual care team. The adaptive component applies only in the intervention arm, potentially guiding subsequent CDS messaging if initial encounters do not show SGLT2i consideration.

Why it matters

Who can join: the full rules

Inclusion Criteria for Providers and Pharmacists:

* Assigned to work in a primary care specialty as a medical provider or assigned to work as a clinic pharmacist
* Assigned to work in one of the participating study clinics

Inclusion Criteria for Patients:

* Scheduled to be seen in a participating clinic with a physician or advanced practice provider in a primary care specialty or a clinic pharmacist
* Medical history of acute kidney injury during a hospitalization with discharge within 1 year before the scheduled appointment
* Medical history of type 2 diabetes mellitus (by billing code)
* Age 30 to 75 years at the date of study enrollment
* Available eGFR from labs more than 3 business days before the scheduled appointment and after AKI onset that is at least 30 mL/min/1.73 m²
* Either a serum creatinine lab measured after discharge from the hospitalization including the AKI, or the last serum creatinine lab during the hospitalization with AKI is less than 0.3 mg/dL above the patient's baseline serum creatinine concentration

Exclusion Criteria for Providers and Pharmacists:

* None

Exclusion Criteria for Patients:

* Opted out of research use of AHC/M Health Fairview data shelter data
* History of kidney transplantation as a recipient(by billing code)
* Pregnancy documented in AHC/M Health Fairview data shelter data (by billing code)
* SGLT2i allergy in the EHR allergy list
* Medical history of diabetic ketoacidosis, dementia, hospice care, or oncology care (by billing code and/or encounter)
* Medical history in the prior 1 year of indwelling Foley urinary catheter, cystitis, pyelonephritis, prostatitis, or urinary tract infection (by billing code)
* Serum creatinine rise of at least 0.3 mg/dL between the two most recent serum creatinine measurements
* Children
* Prisoners

Where it's running

• University of Minnesota
  Minneapolis, Minnesota, United States Recruiting

Study contacts

• Principal investigator: Daniel Murphy — University of Minnesota
• Study coordinator: Daniel P. Murphy
• Email: murph670@umn.edu
• Phone: 612-624-9444

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Reducing surgical bleeding in adults with advanced or acute kidney disease

  This trial will test whether giving tranexamic acid or desmopressin before noncardiac surgery reduces bleeding in adults with advanced chronic kidney disease or recent acute kidney injury, including those on dialysis.

  Recruiting at 2 sites Phase 3 Hamilton Health Sciences Corporation · London, Ontario and 2 other locations · NCT06337838

• Low protein diet combined with dapagliflozin for chronic kidney disease in type 2 diabetes patients

  This study is testing if a low protein diet combined with the medication dapagliflozin can help people with type 2 diabetes and chronic kidney disease slow down their kidney problems.

  Recruiting Phase 4 Anemia Working Group Romania · Bucharest · NCT06281899

• Evaluating kidney and blood pressure outcomes in childhood cancer survivors

  This study is trying to see how common kidney problems and high blood pressure are in childhood cancer survivors a few years after their treatment.

  Recruiting The Hospital for Sick Children · Toronto, Ontario · NCT06153147

• Understanding chronic kidney disease in Sub-Saharan Africa

  This study is trying to understand how common chronic kidney disease is in Sub-Saharan Africa and what factors might be causing it by looking at the health and lifestyle of adults in the Bagamoyo district.

  Recruiting Swiss Tropical & Public Health Institute · Bagamoyo, Pwani Region · NCT05881447

• Using advanced imaging to analyze kidney biopsies for better diagnosis of kidney conditions

  This study is testing a new imaging technique to see if it can help doctors diagnose kidney problems more accurately and quickly in adults who need a biopsy.

  Recruiting Centre Hospitalier William Morey - Chalon sur Saône · Chalon-sur-Saône, Saône-et-Loire · NCT05728216

• Understanding the molecular causes and risks of kidney and related diseases

  This study is trying to understand the genetic and environmental factors that cause kidney diseases and their complications to help improve treatment and care for people at risk or already diagnosed.

  Recruiting University Hospital, Toulouse · Toulouse · NCT05318196

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.